Excellent growth and progress in H1 2026

What a start to 2026! We announced excellent financial results today.

Total sales grew by 23.5% at constant exchange rates, driven by double-digit sales growth in all three therapeutic areas: +15.6% in Oncology, +108.0% in Rare Disease and +16.6% in Neuroscience.

This follows a series of announcements that highlight the great progress we have made since January: two acquisitions and three positive topline results in clinical trials in both chronic and episodic migraine, as well as in primary biliary cholangitis.

https://www.ipsen.com/stories/financial-results/h-2026